Open AccessLong‐Term Clinical Efficacy of Cutting Balloon Angioplasty Followed by Bare Metal Stent Implantation for Treating Ostial Left Anterior Descending Artery Lesions
Author(s) -
Gao LiJian,
Chen JiLin,
Chen Jun,
Yang YueJin,
Gao RunLin,
Li JianJun,
Qin XueWen,
Qiao ShuBin,
Xu Bo,
Yao Min,
Liu HaiBo,
Wu YongJian,
Yuan JinQing,
Chen Jue,
You ShiJie,
Dai Jun
Publication year - 2009
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.20400
Subject(s) - medicine , angioplasty , balloon , cutting balloon , stent , surgery , cardiology , artery , bare metal stent , bare metal , restenosis , drug eluting stent
Background Drug‐eluting stents (DES) are superior to bare metal stents (BMS) for treating ostial left anterior descending artery (LAD) lesions, but DES is not suitable for all patients in real life practice. Hypothesis We hypothesize that cutting balloon angioplasty (CBA) followed by BMS (CBA + BMS) for treating ostial LAD lesions is an alternative strategy. Methods In our study, 101 consecutive patients (51 with DES and 50 with CBA + BMS) with ostial LAD stenting were included for retrospective investigation between November 2003 and May 2005. The target vessel diameter was ≥3.0 mm. Results We compared the DES group with the CBA + BMS group, the rates of restenosis (10.3% versus 17.9%, p = 0.386), target lesion revascularization (TLR) (5.88% versus 10%, p = 0.487) and major adverse cardiac events (MACE) (7.84% versus 12%, p = 0.525) were similar at 6–8 months angiographic follow‐up, but there were higher bleeding events in the DES group ( p = 0.033). During a 2‐year clinical follow‐up, no myocardial infarction occurred in the 2 groups, the rates of TLR (7.84% versus 10%, p = 0.741) and MACE (9.8% versus 12%, p = 0.723) were also similar. The MACE‐free survival rate was 90.2% versus 88 % ( p = 0.723). Conclusions The CBA + BMS combination has a good long‐term clinical effect in the treatment of ostial LAD lesions; it might be an alternative strategy for patients with contraindication for DES implantation, or patients who cannot endure long‐term dual antiplatelet medication, or in elderly patients. Copyright © 2009 Wiley Periodicals, Inc.